Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 15;8(2):62.
doi: 10.3390/antibiotics8020062.

A 2-Year Single-Centre Audit on Antibiotic Resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae Strains from an Intensive Care Unit and Other Wards in a General Public Hospital in Greece

Georgios Feretzakis  1   2   3 , Evangelos Loupelis  4 , Aikaterini Sakagianni  5 , Nikoletta Skarmoutsou  6 , Sophia Michelidou  7 , Aikaterini Velentza  8 , Maria Martsoukou  9 , Konstantinos Valakis  10 , Stavroula Petropoulou  11 , Emmanouil Koutalas  12
Affiliations

A 2-Year Single-Centre Audit on Antibiotic Resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae Strains from an Intensive Care Unit and Other Wards in a General Public Hospital in Greece

Georgios Feretzakis et al. Antibiotics (Basel). .

Abstract

Hospital-acquired infections, particularly in the critical care setting, are becoming increasingly common during the last decade, with Gram-negative bacterial infections presenting the highest incidence among them. Multi-drug-resistant (MDR) Gram-negative infections are associated with high morbidity and mortality, with significant direct and indirect costs resulting from long hospitalization due to antibiotic failure. As treatment options become limited, antimicrobial stewardship programs aim to optimize the appropriate use of currently available antimicrobial agents and decrease hospital costs. Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae are the most common resistant bacteria encountered in intensive care units (ICUs) and other wards. To establish preventive measures, it is important to know the prevalence of Gram-negative isolated bacteria and antibiotic resistance profiles in each ward separately, compared with ICUs. In our single centre study, we compared the resistance levels per antibiotic of P. aeruginosa, A. baumannii and K.pneumoniae clinical strains between the ICU and other facilities during a 2-year period in one of the largest public tertiary hospitals in Greece. The analysis revealed a statistically significant higher antibiotic resistance of the three bacteria in the ICU isolates compared with those from other wards. ICU strains of P. aeruginosa presented the highest resistance rates to gentamycin (57.97%) and cefepime (56.67%), followed by fluoroquinolones (55.11%) and carbapenems (55.02%), while a sensitivity rate of 97.41% was reported to colistin. A high resistance rate of over 80% of A. baumannii isolates to most classes of antibiotics was identified in both the ICU environment and regular wards, with the lowest resistance rates reported to colistin (53.37% in ICU versus an average value of 31.40% in the wards). Statistically significant higher levels of resistance to most antibiotics were noted in ICU isolates of K. pneumoniae compared with non-ICU isolates, with the highest difference-up to 48.86%-reported to carbapenems. The maximum overall antibiotic resistance in our ICU was reported for Acinetobacter spp. (93.00%), followed by Klebsiella spp. (72.30%) and Pseudomonas spp. (49.03%).

Keywords: Acinetobacter baumannii; Klebsiella pneumoniae; Pseudomonas aeruginosa; antibiotic resistance; antimicrobial resistance; intensive care unit.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Resistance rates for Pseudomonas aeruginosa per ward during the 2-year period (2017–2018).
Figure 2
Figure 2
Resistance rates for Acinetobacter baumannii per ward during the 2-year period (2017–2018).
Figure 3
Figure 3
Resistance rates for Klebsiella pneumoniae per ward during the 2-year period (2017–2018).
See this image and copyright information in PMC

References

    1. Gandra S., Barter D.M., Laxminarayan R. Economic burden of antibiotic resistance: How much do we really know? Clin. Microbiol. Infect. 2014;20:973–979. doi: 10.1111/1469-0691.12798. - DOI - PubMed
    1. Cassini A., Högberg L.D., Plachouras D., Quattrocchi A., Hoxha A., Simonsen G.S., Colomb-Cotinat M., Kretzschmar M.E., Devleesschauwer B., Cecchini M., et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019;19:56–66. doi: 10.1016/S1473-3099(18)30605-4. - DOI - PMC - PubMed
    1. Potron A., Poirel L., Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int. J. Antimicrob. Agents. 2015;45:568–585. doi: 10.1016/j.ijantimicag.2015.03.001. - DOI - PubMed
    1. European Centre for Disease Prevention and Control . Antimicrobial Resistance Surveillance in Europe 2015. ECDC; Stockholm, Sweden: 2017. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)
    1. Albiger B., Glasner C., Struelens M.J., Grundmann H., Monnet D.L., European Survey of Carbapenemase-Producing Enterobacteriaceae Working Group Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015;20:30062. doi: 10.2807/1560-7917.ES.2015.20.45.30062. - DOI - PubMed

LinkOut - more resources